Plain-English translation of NCT07916480 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atopic Dermatitis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , a new topical medication designed to treat moderate to severe atopic dermatitis (eczema). The study will involve about 415 participants aged 6 and older who will apply the medication or a placebo cream once daily. Researchers want to see if this treatment can reduce itching, redness, and other uncomfortable symptoms of eczema.
Many people with moderate to severe eczema struggle with current treatment options that don't work well enough or have unwanted side effects. This medication aims to provide a new, easier way to control eczema symptoms by applying it directly to the skin once a day.
You likely qualify if…
You likely don't qualify if…
You'll start with a 4-week phase where you're randomly assigned to apply either the new medication or a placebo cream once daily—you and your doctor won't know which one you're using. During this time, you'll have study visits to check how your skin is responding. If you complete this phase, you can continue into a 48-week extension where everyone receives the active medication, for a total study duration of 52 weeks. Throughout, the research team will monitor your skin, check for any side effects, and take measurements to see how well the treatment works.
AI-generated summary from trial data · Nov 10, 2026 · Not medical advice
United States